Medical Editor: John P. Cunha, DO, FACOEP
CIS-Sulfur Colloid Kit for Preparation of Technetium Tc99m Sulfur Colloid Injection is a diagnostic aid used for imaging areas of functioning reticuloendothelial cells in the liver, spleen and bone marrow; for esophageal transit studies, gastroesophageal reflux scintigraphy, and for the detection of pulmonary aspiration of gastric contents; and as an imaging agent to aid in the evaluation of peritoneo-venous (LaVeen) shunt patency. Common side effects of CIS-Sulfur Colloid Kit for Preparation of Technetium Tc99m Sulfur Colloid Injection include:
- cardiopulmonary arrest
- anaphylactic shock
- low blood pressure
- abdominal pain
- dizziness, and
- burning at the injection site
The dose of CIS-Sulfur Colloid Kit depends on the procedure being performed. CIS-Sulfur Colloid Kit may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, CIS-Sulfur Colloid Kit should be used only if prescribed. This drug passes into breast milk. Formula feeding should be substituted for breastfeeding.
Our CIS-Sulfur Colloid Kit for Preparation of Technetium Tc99m Sulfur Colloid Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following adverse reactions have been reported associated with the use of Technetium Tc 99m Sulfur Colloid Injection: cardiopulmonary arrest, seizures, anaphylactic shock, hypotension, dyspnea, abdominal pain, fever, chills, bronchospasm, nausea, vomiting, perspiration, redness, urticaria, numbness, dizziness and burning at the injection site.
Several deaths and cases of lung and soft tissue uptake other than RES have been reported in association with the use of Technetium Tc 99m Sulfur Colloid Injection (see WARNINGS).
The size and physical-chemical properties of the sulfur colloid particles formed from the components of the kit may determine the biodistribution of the colloid and its uptake by the RE system. Diseases affecting the RE system may also alter the expected uptake pattern.
Read the entire FDA prescribing information for CIS-Sulfur Colloid (CIS-Sulfur Colloid)
© CIS-Sulfur Colloid Patient Information is supplied by Cerner Multum, Inc. and CIS-Sulfur Colloid Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.